Publikationen Gutjahr

Publikationen Dr. Julia Gutjahr

Rot A, Gutjahr JC, Biswas A, Aslani M, Hub E, Thiriot A, von Andrian UH, Megens RTA, Weber C, Duchene J. 2022. Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1. Cell Stem Cell Jul 7;29(7):1013-1015. doi: 10.1016/j.stem.2021.11.010.
Gutjahr JC, Crawford KS, Jensen DR, Naik P, Peterson FC, Samson GPB, Legler DF, Duchene J, Veldkamp CT, Rot A, Volkman BF. 2021. The dimeric form of CXCL12 binds to atypical chemokine receptor 1. Sci Signal Aug 17;14(696):eabc9012. doi: 10.1126/scisignal.abc9012.
Werth K, Hub E, Gutjahr JC, Bosjnak B, Zheng X, Bubke A, Russo S, Rot A, Förster R. 2021. Expression of ACKR4 demarcates the "peri-marginal sinus," a specialized vascular compartment of the splenic red pulp. Cell Rep Jul 13;36(2):109346. doi: 10.1016/j.celrep.2021.109346.
Yu X, Munoz-Sagredo L, Streule K, Muschong P, Bayer E, Walter RJ, Gutjahr JC, Greil R, Concha ML, Müller-Tidow C, Hartmann TN, Orian-Rousseau V. 2021. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues. Blood Sep 23;138(12):1067-1080. doi: 10.1182/blood.2020006343.
Gutjahr JC, Bayer E, Yu X, Laufer JM, Höpner JP, Tesanovic S, Härzschel A, Auer G, Rieß T, Salmhofer A, Szenes E, Haslauer T, Durand-Onayli V, Ramspacher A, Pennisi SP, Artinger M, Zaborsky N, Chigaev A, Aberger F, Neureiter D, Pleyer L, Legler DF, Orian-Rousseau V, Greil R, Hartmann TN. 2021. CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity. Haematologica Aug 1;106(8):2102-2113. doi: 10.3324/haematol.2019.231944.
Szenes E, Härzschel A, Decker S, Tissino E, Pischeli J, Gutjahr JC, Kissel S, Pennisi S, Höpner JP, Egle A, Zaborsky N, Dierks C, Follo M, Chigaev A, Zucchetto A, Greil R, Gattei V, Hartmann TN. 2020. TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia. Leukemia Sep;34(9):2498-2502. doi: 10.1038/s41375-020-0759-3.
Gutjahr JC, Szenes E, Tschech L, Asslaber D, Schlederer M, Roos S, Yu X, Girbl T, Sternberg C, Egle A, Aberger F, Alon R, Kenner L, Greil R, Orian-Rousseau V, Hartmann TN. 2018. Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia. Blood Mar 22;131(12):1337-1349. doi: 10.1182/blood-2017-08-802462.
Tissino E, Benedetti D, Herman SEM, Ten Hacken E, Ahn IE, Chaffee KG, Rossi FM, Dal Bo M, Bulian P, Bomben R, Bayer E, Härzschel A, Gutjahr JC, Postorino M, Santinelli E, Ayed A, Zaja F, Chiarenza A, Pozzato G, Chigaev A, Sklar LA, Burger JA, Ferrajoli A, Shanafelt TD, Wiestner A, Del Poeta G, Hartmann TN, Gattei V, Zucchetto A. 2018. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. J Exp Med Feb 5;215(2):681-697. doi: 10.1084/jem.20171288.
Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, Steiner M, Gutjahr JC, Pleyer L, Egle A, Hartmann TN, Greil R, Geisberger R. 2017. TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. Oncoimmunology Sep 21;7(1):e1371399. doi: 10.1080/2162402X.2017.1371399. eCollection 2017.
Ganghammer S, Gutjahr J, Hutterer E, Krenn PW, Pucher S, Zelle-Rieser C, Jöhrer K, Wijtmans M, Leurs R, Smit MJ, Gattei V, Greil R, Hartmann TN. 2016. Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. Haematologica Mar;101(3):e99-102. doi: 10.3324/haematol.2015.133470.
Gutjahr JC, Greil R, Hartmann TN. 2015. The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia. Front Immunol Apr 20;6:177. doi: 10.3389/fimmu.2015.00177. eCollection 2015.